A 12-week, Open-Label Extension Study of Lurasidone (SM-13496) in Subjects with Schizophrenia

Trial Profile

A 12-week, Open-Label Extension Study of Lurasidone (SM-13496) in Subjects with Schizophrenia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs Lurasidone (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Sumitomo Dainippon Pharma; Sunovion Pharmaceuticals
  • Most Recent Events

    • 17 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 15 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top